CSCarina Seah

Carina Seah

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Carina Seah has a total of 405 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Using clinical and thrombus characteristics to predict the etiology of ischemic stroke: An analysis of the INSIGHT registry

    by Graham A. Branscom, Carina Seah, Tannishtha Som, James Vicari, Alan R. Dabney, Selva Baltan, Farida Sohrabji, Keith Pennypacker, Keith B. Woodward, Benjamin I. Rapoport, et al.

  • Open Access

    Estradiol modulates neuronal network hyperexcitability in select NDD risk genes

    by April Pruitt, Liang Yang, Seoyeon Lee, Novin Balafkan, Carina Seah, Yi Dai, Elizabeth Davidson, Suha Khan, Annabel Sen, Jenny Liu, et al.

    The biological basis for the male sex bias in autism spectrum disorder (ASD) is poorly understood. Differential exposure to sex hormones during neurodevelopment has been proposed as a potential modulator of risk. To test the hypothesis that early exposure to the principal biologically active estrogen, 17β-estradiol, confers a protective effect against mutations in ASD and neurodevelopmental disorder (NDD) genes, we conduct a dual-system multi-modal screen of 36 functionally diverse, large-effect ASD/NDD genes in human induced pluripotent stem cell and larval zebrafish models. We uncover estradiol-dependent effects across genes and modalities, revealing convergent and divergent gene-by-estradiol interactions at the transcriptomic, circuit, and behavioral levels. Estradiol broadly ameliorates ASD/NDD gene expression patterns across all knockouts examined and selectively dampens network hyperexcitability phenotypes in human neurons and zebrafish brains in a subset of ASD/NDD genes ( ASH1L , SCN2A, ANK2, CACNA1G, SHANK3) . Two genes, ASH1L and SCN2A , show comprehensive estradiol rescue of differential gene expression and network bursting activity in human neurons as well as sleep-wake and visual-startle phenotypes in larval zebrafish mutants. Moreover, estradiol rescues seizures and regional increases in brain activity in SCN2A larval zebrafish mutants. Altogether, we describe novel roles of estradiol in modulating network hyperexcitability in the context of loss of function mutations of select ASD/NDD genes.


  • Open Access

    Functional implications of polygenic risk for schizophrenia in human neurons

    by Pj Michael Deans, Kayla G. Retallick-Townsley, Aiqun Li, Carina Seah, Jessica Johnson, Judit Garcia Gonzalez, Evan Cao, Nadine Schrode, Alex Yu, Sam Cartwright, et al.

    Genome wide association studies of schizophrenia reveal a complex polygenic risk architecture comprised of hundreds of risk variants; most are common in the population, non-coding, and act by genetically regulating the expression of one or more gene targets (“eGenes”). It remains unclear how the myriad genetic variants that are predicted to confer individually small effects combine to yield substantial clinical impacts in aggregate. Here, we demonstrate that convergence (i.e., the shared downstream transcriptomic changes with a common direction of effect), resulting from one-at-a-time perturbation of schizophrenia eGenes, influences the outcome when eGenes are manipulated in combination. In total, we apply pooled and arrayed CRISPR approaches to target 21 schizophrenia eGenes in human induced pluripotent stem cell-derived glutamatergic neurons, finding that functionally similar eGenes yield stronger and more specific convergent effects. Points of convergence constrain additive relationships between polygenic risk loci: consistent with a liability threshold model, combinatorial perturbations of these same schizophrenia eGenes reveal that pathway-level convergence predicts when observed effects will fail to sum to levels predicted by an additive model. Targeting points of convergence as novel therapeutic targets may prove more efficacious than individually reversing the effects of multiple risk loci.


  • Single-Cell Sequencing of Human Neural Organoids in a Model of Intracerebral Hemorrhage Reveals Temporally Dynamic Responses to Blood

    by Carina Seah, Braxton R. Schuldt, James M. Vicari, Connie S. Lebakken, William D. Richards, Kaylie Greuel, Kailyn T. Parham, Grace Rabinowitz, Christopher P. Kellner

    BACKGROUND: Intracerebral hemorrhage leads to significant morbidity and mortality due to primary mechanical and secondary neurotoxic injury to brain parenchyma. Timing of surgical evacuation to ensure optimal outcomes is controversial, with recent evidence suggesting early intervention improves functional outcome. Here, we characterize the impact of blood-induced secondary injury on diverse brain cell types in a scalable organoid model of intracerebral hemorrhage. METHODS: Human neural organoids consisting of excitatory neurons, inhibitory neurons, neural progenitor cells, astrocytes, endothelial cells, and microglia were generated from induced pluripotent stem cell–derived cells and treated with 5% blood for either 6 or 24 hours. Organoids were dissociated and analyzed by single-cell RNA sequencing. RESULTS: Single-cell sequencing of 96 725 cells across 18 organoids resolved intermediate progenitors, neural progenitor cells, microglia, inhibitory neurons, endothelial cells, excitatory neurons, and astrocytes. Twenty-four-hour exposure to blood induced cellular reactivity, whereas 6-hour exposure did not. Intermediate progenitors, endothelial cells, and astrocytes were the most reactive to blood and exhibited gene expression patterns corresponding to astrocyte reactivity, angiogenesis, and progenitor cell ischemic excitotoxicity. Drug repurposing analysis identified neurotransmitter-modulating, vasculature-remodeling, and protein synthesis pathways as potential therapeutic targets, mitigating blood-induced neurotoxicity. CONCLUSIONS: Blood exposure induces transcriptomic changes in a temporal and cell type–specific manner, particularly mediated by astrocyte reactivity, angiogenesis, and impairment of neurogenesis. Early and complete removal of blood after 6 hours of blood exposure mitigates secondary neurotoxicity seen in 24-hour exposure to blood. Transcriptomic signatures of blood-mediated neurotoxicity may potentially be reversed by antiadrenergic, dopamine agonist, and vasodilatory mechanisms.


  • Open Access

    The impact of chronic pain on brain gene expression

    by Lily Collier, Carina Seah, Emily M. Hicks, Paul E. Holtzheimer, John H. Krystal, Matthew J. Girgenti, Laura M. Huckins, Keira J. A. Johnston

    Chronic pain affects one-fifth of American adults, contributing significant public health burden. Chronic pain can be further understood through investigating brain gene expression, potentially informing on brain regions, cell types, and gene pathways. We tested for differentially expressed genes (DEGs) in chronic pain, migraine, lifetime fentanyl and oxymorphone use, and with chronic pain genetic risk in 4 brain regions (dorsal anterior cingulate cortex [dACC], dorsolateral prefrontal cortex [DLPFC], medial amygdala [MeA], and basolateral amygdala [BLA]) and imputed cell type expression data from 304 deeply phenotyped postmortem donors, potentially highlighting variation relevant to factors such as predisposition to chronic pain development, mechanisms of chronic pain development and persistence, and indirect effects of chronic pain and associated treatment or medication, and substance use. We also investigated sex differences in chronic pain differential gene expression. At the brain region level, we identified 2 chronic pain DEGs: B4GALT2 and VEGFB in dACC. At the cell level, we found more than 2000 chronic pain cell-type DEGs, significantly enriched in microglia of the basolateral amygdala. The findings were enriched for mouse microglia pain genes, and for hypoxia and immune response pathways. Small amounts of cross-trait DEG overlap in migraine and chronic pain highlighted medial amygdala cells, and in chronic pain and oxymorphone use suggested the amygdala as a key region. Chronic pain differential gene expression was not significantly different between men and women. Overall, chronic pain-associated gene expression is heterogeneous across region and cell type, is largely distinct from that in pain-related factors and migraine, and our results highlight BLA microglia as a key brain cell type in chronic pain.


  • Open Access

    A computational genetic- and transcriptomics-based study nominates drug repurposing candidates for the treatment of chronic pain

    by Alanna C. Cote, Keira J.A. Johnston, Carina Seah, Hannah Young, Laura M. Huckins

    Summary: Chronic pain, defined as pain that persists for greater than three months, is a common, understudied condition that affect an estimated 20-30% of the population 1,2 . Despite a high prevalence and distressing physical and psychological symptoms, research is lacking in appropriate long-term pharmaceutical treatment for chronic pain, and chronic pain persists at high rates even with intervention. Recent genome-wide association studies (GWAS) of chronic pain indicate that chronic pain can be studied as a distinct neuropsychiatric illness with genetic risk 3,4 . Here we develop a genetics-informed framework to identify new drug repurposing candidates for chronic pain. We first use a functional genomics approach to drug repurposing, called signature mapping, to identify drug repurposing candidates for chronic pain 5 . In a signature mapping analysis, the transcriptomic effects of disease and drug perturbations are compared, and drugs with opposite effects on gene expression as the disease are nominated as therapeutic candidates. Then we further investigate therapeutic avenues through causal inference using two-sample Mendelian randomization analysis, leveraging GWAS of chronic pain and GWAS of medication use across 23 drug classes. This approach, driven by information from genome- and transcriptome-wide associations with chronic pain, can yield additional insights beyond the single receptor- or molecule-level drug discovery investigation in traditional drug development pipelines.

  • Open Access

    Implications of gene × environment interactions in post-traumatic stress disorder risk and treatment

    by Carina Seah, Anne Elizabeth Sidamon-Eristoff, Laura M. Huckins, Kristen J. Brennand

    Exposure to traumatic stress is common in the general population. Variation in the brain’s molecular encoding of stress potentially contributes to the heterogeneous clinical outcomes in response to traumatic experiences. For instance, only a minority of those exposed to trauma will develop post-traumatic stress disorder (PTSD). Risk for PTSD is at least partially heritable, with a growing number of genetic factors identified through GWAS. A major limitation of genetic studies is that they capture only the genetic component of risk, whereas PTSD by definition requires an environmental traumatic exposure. Furthermore, the extent, timing, and type of trauma affects susceptibility. Here, we discuss the molecular mechanisms of PTSD risk together with gene × environment interactions, with a focus on how either might inform genetic screening for individuals at high risk for disease, reveal biological mechanisms that might one day yield novel therapeutics, and impact best clinical practices even today. To close, we discuss the interaction of trauma with sex, gender, and race, with a focus on the implications for treatment. Altogether, we suggest that predicting, preventing, and treating PTSD will require integrating both genotypic and environmental information.


  • Open Access

    Radiomic Consensus Clustering in Glioblastoma and Association with Gene Expression Profiles

    by Tadeusz H. Wroblewski, Mert Karabacak, Carina Seah, Raymund L. Yong, Konstantinos Margetis

    Background/Objectives: Glioblastoma (GBM) is the most common malignant primary central nervous system tumor with extremely poor prognosis and survival outcomes. Non-invasive methods like radiomic feature extraction, which assess sub-visual imaging features, provide a potentially powerful tool for distinguishing molecular profiles across groups of patients with GBM. Using consensus clustering of MRI-based radiomic features, this study aims to investigate differential gene expression profiles based on radiomic clusters. Methods: Patients from the TCGA and CPTAC datasets (n = 114) were included in this study. Radiomic features including T1, T1 with contrast, T2, and FLAIR MRI sequences were extracted using PyRadiomics. Selected radiomic features were then clustered using ConsensusClusterPlus (k-means base algorithm and Euclidean distance), which iteratively subsamples and clusters 80% of the data to identify stable clusters by calculating the frequency in which each patient is a member of a cluster across iterations. Gene expression data (available for n = 69 patients) was analyzed using differential gene expression (DEG) and gene set enrichment (GSEA) approaches, after batch correction using ComBat-seq. Results: Three distinct clusters were identified based on the relative consensus matrix and cumulative distribution plots (Cluster 1, n = 25; Cluster 2, n = 46; Cluster 3, n = 43). No significant differences in patient demographic characteristics, MGMT methylation status, tumor location, or overall survival were identified across clusters. Differentially expressed genes were identified in Cluster 1, which have been previously associated with GBM prognosis, recurrence, and treatment sensitivity. GSEA of Cluster 1 showed an enrichment of genes upregulated for immune-related and DNA metabolism pathways and genes downregulated in pathways associated with protein and histone deacetylation. Clusters 2 and 3 exhibited fewer DEGs which failed to reach significance after multiple testing corrections. Conclusions: Consensus clustering of radiomic features revealed unique gene expression profiles in the GBM cohort which likely represent subtle differences in tumor biology and radiosensitivity that are not visually discernible, underscoring the potential of radiomics to serve as a non-invasive alternative for identifying GBM molecular heterogeneity. Further investigation is still required to validate these findings and their clinical implications.


  • Open Access

    Decoding the transcriptomic signatures of psychological trauma in human cortex and amygdala

    by Emily M. Hicks, Carina Seah, Michael Deans, Seoyeon Lee, Keira J.A. Johnston, Alanna Cote, Julia Ciarcia, Akash Chakka, Lily Collier, Paul E. Holtzheimer, et al.

    Psychological trauma has profound effects on brain function and precipitates psychiatric disorders in vulnerable individuals, however, the molecular mechanisms linking trauma with psychiatric risk remain incompletely understood. Using RNA-seq data postmortem brain tissue of a cohort of 304 donors (N=136 with trauma exposure), we investigated transcriptional signatures of trauma exposures in two cortical regions (dorsolateral prefrontal cortex, and dorsal anterior cingulate cortex) and two amygdala regions (medial amygdala and basolateral amygdala) associated with stress processing and regulation. We focused on dissecting heterogeneity of traumatic experiences in these transcriptional signatures by investigating exposure to several trauma types (childhood, adulthood, complex, single acute, combat, and interpersonal traumas) and interactions with sex. Overall, amygdala regions were more vulnerable to childhood traumas, whereas cortical regions were more vulnerable to adulthood trauma (regardless of childhood experience). Using cell-type-specific expression imputation, we identified a strong transcriptional response of medial amygdala excitatory neurons to childhood trauma, which coincided with dysregulation observed in a human induced pluripotent stem cell (hiPSC)-derived glutamatergic neurons exposed to hydrocortisone. We resolved multiscale coexpression networks for each brain region and identified modules enriched in trauma signatures and whose connectivity was altered with trauma. Trauma-associated coexpression modules provide insight into coordinated functional dysregulation with different traumas and point to potential gene targets for further dissection. Together, these data provide a characterization of the long-lasting human encoding of traumatic experiences in corticolimbic regions of human brain.